Genflow Biosciences PLC Announces Second European Patent Application
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) announced publication of its second European patent application (Application No. 23821586.7; Publication No. EP4630038) titled “SIRT6 Variant for NASH” in the European Patent Bulletin on October 22, 2025.
The publication follows entry into the European phase under the PCT and provides provisional protection under Article 67(3) EPC, enabling retroactive damages for infringing acts after publication once the patent is granted and national validations are completed. The filing complements the company’s earlier EP4338267 SIRT6 variant application and is presented as part of Genflow’s strategy to expand IP coverage across metabolic and age‑related disorders and support upcoming clinical programs.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) ha annunciato la pubblicazione della sua seconda domanda di brevetto europea (Numero di domanda 23821586.7; Pubblicazione n. EP4630038) intitolata “SIRT6 Variant for NASH” nel European Patent Bulletin il 22 ottobre 2025.
La pubblicazione segue l'ingresso nella fase europea sotto il PCT e offre protezione provvisoria ai sensi dell'articolo 67(3) EPC, consentendo la possibilità di richieste di risarcimento retroattivo per atti di violazione dopo la pubblicazione una volta che il brevetto sia concesso e siano state concluse le convalide nazionali. La domanda integra l'EP4338267 relativa alla variante SIRT6 ed è presentata come parte della strategia di Genflow di estendere la copertura IP su disordini metabolici e legati all'età, a supporto dei futuri programmi clinici.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) anunció la publicación de su segunda solicitud de patente europea (Número de solicitud 23821586.7; Publicación No. EP4630038) titulada “SIRT6 Variant for NASH” en el European Patent Bulletin el 22 de octubre de 2025.
La publicación sigue la entrada en la fase europea bajo el PCT y proporciona protección provisional conforme al Artículo 67(3) EPC, lo que permite reclamar daños retroactivos por actos de infracción tras la publicación una vez que la patente sea concedida y se completen las validaciones nacionales. El registro complementa la anterior solicitud EP4338267 de variante SIRT6 y se presenta como parte de la estrategia de Genflow para ampliar la cobertura de IP sobre trastornos metabólicos y relacionados con la edad y apoyar los próximos programas clínicos.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF)는 두 번째 유럽 특허 출원(출원번호 23821586.7; 공보번호 EP4630038) 제목 “SIRT6 Variant for NASH”가 2025년 10월 22일 유럽 특허 공보에 게재되었다고 발표했다.
이 공보는 PCT에 따른 유럽 구역 진입에 따라 제67조(3) EPC에 따른 임시 보호를 제공하여 특허가 허가되고 각 국의 검증이 완료된 이후 침해 행위에 대해 소급하여 손해배상 청구가 가능하다. 이 출원은 이전의 EP4338267 SIRT6 변이 출원을 보완하며, 대사 및 연령 관련 질환에 대한 IP 커버리지 확장과 향후 임상 프로그램 지원을 위한 Genflow의 전략의 일부로 제시된다.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) a annoncé la publication de sa deuxième demande de brevet européenne (Numéro de demande 23821586.7; Publication No. EP4630038) intitulée “SIRT6 Variant for NASH” dans le European Patent Bulletin le 22 octobre 2025.
La publication fait suite à l’entrée en phase européenne sous le PCT et offre une protection provisoire en vertu de l’article 67(3) du EPC, permettant des dommages rétroactifs pour les actes d’infraction après publication une fois le brevet délivré et les validations nationales complétées. Le dépôt complète l’application antérieure EP4338267 de variante SIRT6 et est présenté dans le cadre de la stratégie de Genflow visant à étendre la couverture IP sur les troubles métaboliques et liés à l’âge et à soutenir les prochains programmes cliniques.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) gab die Veröffentlichung seines zweiten europäischen Patentantrags bekannt (Anmeldenr. 23821586.7; Veröffentlichungsnr. EP4630038) mit dem Titel “SIRT6 Variant for NASH” im Europäischen Patentblatt am 22. Oktober 2025.
Die Veröffentlichung folgt dem Eintritt in die europäische Phase unter dem PCT und bietet vorläufigen Schutz gemäß Art. 67(3) EPÜ, der rückwirkende Schadensersatzansprüche für Verletzungen nach der Veröffentlichung ermöglicht, sobald das Patent erteilt ist und nationale Validierungen abgeschlossen sind. Die Anmeldung ergänzt den früheren EP4338267 SIRT6-Variante Antrag und wird im Rahmen der Genflow-Strategie präsentiert, den IP-Schutz in Stoffwechsel- und altersbedingten Erkrankungen auszubauen und kommende klinische Programme zu unterstützen.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) أعلنت عن نشر طلبها الثاني لبراءة الاختراع الأوروبية (رقم الطلب 23821586.7؛ رقم النشر EP4630038) بعنوان “SIRT6 Variant for NASH” في النشرة الأوروبية لبراءات الاختراع بتاريخ 22 أكتوبر 2025.
يلي النشر دخولها إلى المرحلة الأوروبية بموجب PCT ويقدم حماية مؤقتة وفق المادة 67(3) من EPC، مما يسمح بمطالبات تعويض رجعي عن أفعال التعدي بعد النشر بمجرد منح البراءة وإتمام التحقق الوطني. الإيداع يكمل الطلب السابق EP4338267 الخاص بمتغير SIRT6 ويُقدَّم كجزء من استراتيجية Genflow لتوسيع تغطية الملكية الفكرية عبر الاضطرابات الأيضية والارتباط بالعمر ودعم البرامج السريرية المقبلة.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) 宣布了其第二份欧洲专利申请的公布（申请号 23821586.7；公开号 EP4630038），题为 “SIRT6 Variant for NASH”，于 2025 年 10 月 22 日在欧洲专利公报上刊登。
该公布在 PCT 下进入欧洲阶段，并提供根据 第 67(3) 条 EPC 的临时保护，专利获批并完成各国验证后可对侵权行为追溯性请求赔偿。该申请补充了早前的 EP4338267 SIRT6 变体申请，并作为 Genflow 扩大在代谢性疾病及与年龄相关疾病领域的知识产权覆盖、支持未来临床项目策略的一部分。
- European patent application EP4630038 published on 22 Oct 2025
- Provisional protection under Article 67(3) EPC from publication
- Complementary to existing EP4338267 SIRT6 filing strengthening IP
- Patent not yet granted; formal grant required for full enforceability
- National validation steps required before rights apply in each EPC state
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Genflow Biosciences Plc
Publication of Second European Patent Application - SIRT6 Variant for NASH
LONDON, UK / ACCESS Newswire / October 22, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), the only publicly listed longevity company in Europe, is pleased to announce that its second European patent application (Application No. 23821586.7, Publication No. EP4630038) titled "SIRT6 Variant for NASH" has been published in the European Patent Bulletin ("EPO").
Publication of the patent application in the European Patent Bulletin follows entry into the European phase under the Patent Cooperation Treaty (PCT) and represents a key milestone in
Genflow's expanding intellectual property (IP) portfolio.
This publication confers provisional protection under Article 67(3) of the European Patent Convention (EPC), enabling Genflow to claim retroactive damages in designated EPC states for infringing acts occurring after the publication date, once the patent is formally granted and national validation requirements are met.
Strategic Significance
This development marks continued progress in Genflow's comprehensive patent strategy to strengthen protection for its SIRT6 gene variant technologies and expand their therapeutic reach across metabolic and age-related disorders, including NASH (non-alcoholic steatohepatitis). It also reinforces Genflow's IP leadership in the longevity and metabolic disease space, complementing the recently published EP4338267 covering the Company's core SIRT6 variant for healthy aging. Together, these filings establish a robust European patent framework supporting Genflow's therapeutic platform and upcoming clinical programs.
Dr. Eric Leire, Chief Executive Officer of Genflow Biosciences, commented: "The publication of our second European patent marks another important validation of our science and IP strategy. With both of our key SIRT6 applications now public and provisionally enforceable in Europe, we have solidified the foundation for long-term value creation, enhanced partnership potential, and future grant protection across our portfolio."
Contacts
Genflow Biosciences | Harbor Access |
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
+32-477-495-881 | +1 475 477 9401 |
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there are no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.
DISCLAIMER
The contents of this announcement have been prepared by, and are the sole responsibility of, the Company.
This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.
Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
FAQ
What did Genflow (GENFF) announce on October 22, 2025 about patents?
What protection does EP4630038 give Genflow (GENFF) after publication?
How does the new EP4630038 filing affect Genflow’s SIRT6 IP position (GENFF)?
Is EP4630038 immediately enforceable across Europe for Genflow (GENFF)?
Will EP4630038 affect Genflow’s upcoming clinical programs (GENFF)?
What are the next steps after Genflow’s (GENFF) European patent publication?
